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40Within the Predict-IV FP7 project a strategy for measurement of in vitro biokinetics was developed,
requiring the characterization of the cellular model used, especially regarding biotransformation, which
frequently depends on cytochrome P450 (CYP) activity. The extrahepatic in situ CYP-mediated metabo-
lism is especially relevant in target organ toxicity. In this study, the constitutive mRNA levels and protein
localization of different CYP isoforms were investigated in 3D aggregating brain cell cultures. CYP1A1,
CYP2B1/B2, CYP2D2/4, CYP2E1 and CYP3A were expressed; CYP1A1 and 2B1 represented almost 80%
of the total mRNA content. Double-immunolabeling revealed their presence in astrocytes, in neurons,
and to a minor extent in oligodendrocytes, conﬁrming the cell-speciﬁc localization of CYPs in the brain.
These results together with the recently reported formation of an amiodarone metabolite following
repeated exposure suggest that this cell culture system possesses some metabolic potential, most likely
contributing to its high performance in neurotoxicological studies and support the use of this model in
studying brain neurotoxicity involving mechanisms of toxication/detoxication.











The cytochrome P450 (CYP) superfamily is one of the most
important groups of enzymes involved in the biotransformation
of a large number of endogenous and exogenous compounds,
including toxic substances, drugs and environmental chemicals.
Although the liver is the primary organ responsible for
CYP-mediated metabolism, the relevance of extrahepatic CYP-
mediated metabolism is widely recognized, especially regarding









722008; Ravindranath and Strobel, 2013; Rieder et al., 1998).
Neurotoxicity is one of the most relevant toxicological end-points,
due to the crucial role played by the central nervous system (CNS)
in the organism functionality.
In the CNS CYPs have been identiﬁed as functional enzymes,
and are known to metabolize in situ a variety of compounds includ-
ing centrally acting drugs, xenobiotics, neurotoxins, endogenous
steroids and neurochemicals (Ravindranath and Strobel, 2013;
Zanger et al., 2004). Different CYP isoforms have been identiﬁed
in the rat CNS using in situ hybridization, catalytic, molecular,
and immunohistochemical techniques. Results showed that drug-
metabolizing CYPs are not homogeneously distributed among
brain regions, which differ widely in cellular composition, cell den-
sity and function. Indeed, they are characterized by a marked
region-speciﬁc distribution, and have been found in neurons, glial
cells and at the blood–brain interface (Meyer et al., 2007; Stamou
et al., 2014).
The expression of CYPs in the whole brain is reported to occur at
only 1% of the levels found in the liver, therefore it is unlikely that
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18 March 2015However, since CYPs can be highly expressed in speciﬁc cells or
brain regions, the metabolism of drugs crossing the blood–brain
barrier can be of relevance and responsible of speciﬁc effects
locally within the brain (Miksys and Tyndale, 2002, 2004).
Similarly to the liver, brain CYPs are responsive to chemicals:
induction can be regulated by several complex mechanisms
(including the increase of mRNA expression) (Johri et al., 2007;
Parmar et al., 2003) which are both tissue and cell-type speciﬁc
(Miksys and Tyndale, 2004). Brain CYPs can be responsive to the
same inducers active on hepatic CYPs (Ghersi-Egea et al., 1987;
Kapoor et al., 2006; Joshi and Tyndale, 2006), although different
induction patterns have been reported (Miksys et al., 2000;
Stamou et al., 2014).
It has been stated that results from in vivo toxicity tests are not
always optimal for neurotoxic effects (Harry and Tiffany-
Castiglioni, 2005), due to the inability to have factors as neuronal,
hormonal and immunological stimuli under full experimental con-
trol. Indeed, some degree of over-prediction of neurotoxic effects
was reported with 45 miscellaneous drugs, particularly when high
doses were tested, showing that high-dose effects such as ataxia
and convulsions in animals might not be relevant in humans
(Fletcher, 1978). Despite the market for drugs used to cure CNS dis-
orders is set to grow substantially in the coming years, due to an
aging population, CNS drugs have a low chance of success in drug
development. This is explained by the complexity of the brain and
the liability of CNS drugs to cause CNS side effects, not always
identiﬁed by traditional neurotoxicity testing for the above-men-
tioned reasons. These observations, together with an increasing
demand for reduction of animal use in toxicological testing,
strongly push toward the development of suitable in vitromethods
for neurotoxicity testing, able to predict neurotoxicity in the early
stage of drug development.
Among several in vitro models used to mimic the brain, aggre-
gating brain cell cultures represent most closely the multicellular
architecture, maturation, and functions of the in vivo brain tissue.
These three-dimensional (3D) cell cultures have been shown to
reach a highly differentiated phenotype that is maintained for at
least two months (Zurich et al., 1998). These characteristics have
made them a precious and useful model system for neurotox-
icological investigations (Honegger et al., 2011; Honegger and
Werffeli, 1988; Zurich et al., 2000, 2013). Although the presence
of CYP activity has previously been suggested (Monnet-Tschudi
et al., 2008, 2000), scant information is available on the metabolic
capability of these 3D cultures, as for most of the available in vitro
models for neurotoxicity.
Generally speaking, the absence of characterization of the meta-
bolic competence of the model used, as well as of information on
the compounds permeability through the blood brain barrier,
strongly limits the interpretation of results of in vitro neurotoxicity
for risk assessment purposes. The EU FP7 Project Predict-IV, which
funded this study, had the overall aim of improving the assessment
of drug safety, by integrating kinetics and dynamics data. Within
the project a strategy for the measurement of in vitro biokinetics
was developed which foresees the characterization of the different
cellular models used.
In this study, we used a combination of quantitative
Reverse Transcription-PCR (qRT-PCR), immunohistochemistry and
western-blot techniques to characterize the expression and the
presence of CYP isoforms and their cell type-speciﬁc localization
in 3D aggregating brain cell cultures. In addition, we explored
the responsiveness of the cells to nicotine to evaluate possible
induction of a panel of different CYPs. Nicotine was selected as a
model inducer, since it has been reported to induce several CYPs
in some rat brain regions after chronic exposure in vivo (Ande
et al., 2012; Joshi and Tyndale, 2006; Miksys et al., 2000; Yue
et al., 2008).Please cite this article in press as: Vichi, S., et al. Cell type-speciﬁc expression a
rat brain cell cultures. Toxicol. in Vitro (2015), http://dx.doi.org/10.1016/j.tiv.22. Materials and methods
2.1. Cell culture and treatments
Serum-free, rotation-mediated aggregating brain cell cultures
were prepared from 16-day embryonic rat brain (Janvier Labs,
France), as described previously in detail (Honegger et al., 2011,
1979). The dissected brains from about 100 embryos – comprising
the telencephalon, mesencephalon and rhombencephalon – were
dissociated mechanically into a single cell fraction by the sequen-
tial passage through nylon sieves of 200-lm and 100-lm pore
sizes. Through all steps of the preparation, the cells were kept in
ice-cold, Ca2+–Mg2+-free saline (Puck’s saline solution D1). The
dissociated cells were washed by centrifugation (15 min, 300 gmax),
and ﬁnally resuspended in cold serum-free culture medium (modi-
ﬁed DMEM). Aliquots of the cell suspension (4 ml, on average con-
taining the amount of cells from one embryonic brain) were
distributed in 100 culture ﬂasks (25-ml modiﬁed Erlenmeyer ﬂasks
with air-permeable stoppers) and incubated under continuous
gyratory agitation (68 rpm) in a CO2 incubator (10% CO2, 90%
humidiﬁed air, 37 C). After two days, the cultures were transferred
to larger ﬂasks (50-ml modiﬁed Erlenmeyer ﬂasks with air-perme-
able stoppers) and supplemented with 4 ml of fresh medium. The
frequency of gyratory agitation was increased progressively from
68 rpm at culture initiation day in vitro (DIV) 0, to 70 rpm (evening
of DIV 0), then to 74 rpm (DIV 1), 78 rpm (DIV 2, after the culture
transfer), and then to the ﬁnal speed of 80 rpm (DIV 4) which was
kept throughout the following culture period. Culture media was
replenished by the exchange of 5 ml of medium (of a total of
8 ml) per ﬂask, at intervals of 3 days until DIV 14, and at intervals
of 2 days thereafter. For experimentation, the aggregates of several
original ﬂasks were pooled and redistributed in order to prepare
replicate cultures each containing about 200 free-ﬂoating aggre-
gates (equivalent to about 1/6 of the original ﬂask). The replicates
were kept under standard culture conditions.
Nicotine hydrogen tartrate salt was purchased from Sigma and
stock solutions were prepared in H2O and neutralized against
phenol red with NaOH. Cultures were exposed to nicotine
(50–200 lM) during 4 h, 24 h, and 48 h. Aliquots of the stock solu-
tions were added directly to the culture supernatants. Control cul-
tures received an equal volume of the solvent. The ﬁnal
concentration of DMSO in the culture medium was 0.05% (V/V).
For each group of treatment, 3 replicate cultures, coming from
the same pool of embryonic brains, were used. Three experiments
were performed at DIV20, and three experiments at DIV33. These
experiments were performed on aggregates prepared from four
independent pools of embryonic brains.2.2. RNA extraction and cDNA synthesis
Total mRNA was extracted from aggregating brain cell cultures
using the QIAshredder and total RNeasy kits from Qiagen, accord-
ing to manufacturer’s instructions and eluted in RNase-free water.
The RNA concentration and purity was determined by measuring
UV absorbance at 260 and 280 nm using the NanoDrop ND-1000
UV–Vis Spectrophotometer (Nanodrop Technologies). cDNA was
synthesized from 1 lg of total RNA in a total volume of 20 ll using
the Applied High Capacity cDNA Reverse Transcription kit (Life
Technologies). The obtained transcripts were stored at-20 C and
analyzed by qRT-PCR methodology.2.3. Quantitative real-time PCR
Quantitative analysis of CYP mRNA expression was performed
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18 March 2015using 96-well optical reaction plates in a StepOne™ Real-Time PCR
System (Life Technologies).
The levels of CYP1A1, CYP1A2, CYP2B1, CYP3A1 and CYP3A2
mRNAs were determined using TaqMan chemistry according to
the method described by Meredith et al. (2003), with thermal con-
ditions of an initial two-step holding stage at 50 C for 2 min and
subsequent denaturation at 95 C for 10 min, followed by 40
cycling stages of denaturation at 95 C for 15 s and annealing/ex-
tension at 60 C for 1 min. TaqMan probes were labeled on the
50-end with FAM as the ﬂuorophore dye and on the 30-end with
TAMRA as the quencher dye.
The levels of CYP2D2, CYP2E1 and CYP2D4/2D6 mRNAs were
measured applying SYBR-green chemistry following the method
of Mrozikiewicz et al. (2010) and Yoshida et al. (2002) with the
same thermal proﬁle as described above for the PCR ampliﬁcation,
with the addition of a ﬁnal melting curve stage.
Quantitation of copies of mRNA of each tested CYP was calcu-
lated from the experimental threshold cycle value (Ct), by inter-
polation from the standard curve generated using serial dilution
of known cDNA concentrations. For each tested CYP a ﬁve-point
standard curve was constructed. The mRNA levels obtained for
each CYP were normalized with respect to the mRNA levels deter-
mined for Cyclophilin A, selected as housekeeping gene. Primers
and TaqMan probes for Cyclophilin A were designed using
Primer Express v. 3.0 software (AB-Life Technologies) and
custom-synthesized by AB-Life Technologies. Cyclophilin A was
co-ampliﬁed in a simultaneous reaction together with the CYPs,
under the same experimental conditions and with a similar PCR
efﬁciency with respect to the target gene. Technical duplicates
were performed for each real time reactions. After treatment with
inducers, results of normalized mRNA expression levels were
reported as fold change values with respect to untreated cultures.
All primers and TaqMan probes used in this study are listed in
Table 1. For each experiment, the coefﬁcient of variation (CV) in
the technical replicates (n = 3) on each replicate cultures was
around 2%.
2.4. Immunohistochemistry
Mature aggregates were washed twice with pre-warmed phos-
phate buffered saline (PBS), embedded in cryomatrix (Thermo
Fisher Scientiﬁc), frozen in liquid nitrogen cooled isopentane, and
stored at 80 C. Cryosections (10 lm) were ﬁxed for 10 min in
4% paraformaldehyde/PBS. Sections were blocked with normal
horse-, goat- or rabbit serum (1:25 in PBS with 0.1% Triton-X100,
Jackson), and subsequently incubated overnight at 4 C with
antibodies against CYP1A1 (H-70) (1:50, rabbit polyclonal, Santa
Cruz), CYP2D4 (1:1000, rabbit polyclonal, Millipore), CYP2E1
(1:2000, rabbit polyclonal, Millipore), CYP2B1/2B2 (1:50, mouse
monoclonal, Santa Cruz) and CYP3A (L-14) (1:200, goat polyclonal,
Santa Cruz). Following, sections were incubated with the
corresponding biotinylated IgG, i.e. horse anti-mouse IgG (1:200,
Vector), goat anti-rabbit IgG (1:200 Vector) and rabbit anti-goat
(1:200, Vector), followed by revelation with FITC-avidin (1:100,
Vector). Determination of the cellular localization of CYP1A1,
CYP2D4, CYP2E1 and CYP3A was achieved by double labeling with
antibodies against astrocytic Glial Fibrillary Acidic Protein (GFAP)
(1:800, mouse monoclonal, Sigma–Aldrich), neuronal phos-
phorylated and non-phosphorylated neuroﬁlaments (1:1000,
mouse monoclonal SMI31, Covance, and mouse monoclonal, Enzo
Life Sciences) and oligodendrocytic myelin basic protein (MBP)
(1:40, mouse monoclonal, Millipore). For CYP2B1/2B2, double
labeling was done with anti GFAP (1:100, rabbit polyclonal,
Sigma–Aldrich) and Microtubule-Associated Protein 2 (MAP-2)
(1:200, rabbit polyclonal, Chemicon). Alexa Fluor 546
donkey anti-mouse, respectively anti-rabbit, IgG (1:400, LifePlease cite this article in press as: Vichi, S., et al. Cell type-speciﬁc expression a
rat brain cell cultures. Toxicol. in Vitro (2015), http://dx.doi.org/10.1016/j.tiv.2Technologies) was used to reveal cell type-speciﬁc labeling.
Hoechst (33342, Molecular Probes) was used to visualize cell
nuclei. Sections were mounted in ProLong Gold antifade reagent
(Life Technologies). Images were acquired on a Nikon Eclipse 90i
ﬂuorescence microscope. Automatic pixel density recognition of
Hoechst labeled area, using ImageJ software, was used to create a
mask for visualization of nuclei (indicated by circular-like white
lines in insets of Fig. 2).
2.5. Western blotting and relative protein content measurement
Mature aggregates were homogenized with glass-Teﬂon doun-
cer in 50 mM NaCl, 20 mM Tris–HCl pH 7.4, 1 mM EDTA, 0.5%
Sodium Deoxycholate 20, and 1 complete protease inhibitor
cocktail (Roche, Switzerland). Protein concentration was
determined by absorbance at 280 nm using NanoDrop ND-1000
UV–Vis Spectrophotometer (Nanodrop Technologies). Lysates were
diluted to the same total protein concentration, and a total quan-
tity of 50 lg/sample and lane was loaded, mixed 1:6 with
Laemmli buffer (375 mM Tris–HCl pH 6.8, 9% SDS, 50% Glycerol,
9% Betamercaptoethanol, 0.03% Bromophenol blue). Samples were
separated on 4–15% TX Page gel (BioRad). Proteins were trans-
ferred to 0.22 lm pore size nitrocellulose membranes (BioRad,
Switzerland) and subsequently stained with ponceau red to ensure
equal loading and proper transfer. Membranes were washed and
blocked over-night at 4 C with 10% non-fat dry milk/20 in mM
Trizma base, 137 mM NaCl, 0.05% Tween, pH 7.6. Membranes were
probed (3 h at room temperature) with primary antibodies against
CYP1A1 (H-70) (1:1000, sc-20772, rabbit polyclonal, Santa Cruz),
CYP2D4 (1:1000, AB1272, rabbit polyclonal, Millipore),
CYP2E1 (1:1000, AB1252, rabbit polyclonal, Millipore), CYP2B1/
2B2 (9.14) (1:500, sc-73546, mouse monoclonal, Santa Cruz) and
CYP3A1 (P6) (1:500, sc-53246, mouse monoclonal, Santa Cruz).
Horseradish peroxidase conjugated secondary goat anti-rabbit,
Advansta (1:10000) and goat anti-mouse, Bio-Rad (1:10000),
antibodies were applied, and subsequently visualized with
chemiluminescence (Western Bright ECL, Advansta).
Autoradiograms were processed using ImageJ to determine den-
sitometry units. For relative quantiﬁcations CYP-band intensity
was normalized to its corresponding load on ponceau red, and
thereafter fold changes were calculated to relative CYP-band inten-
sities in liver. Three replicates were performed for liver, brain, and
brain aggregates. For the semi-quantitative determination of CYP
protein obtained by western blot, the relative band intensity values
of each individual replicate was calculated as fold change with
respect to the mean band intensity of liver samples (set as 1).
2.6. Statistical analysis
In Fig. 4 fold change values obtained for each CYP, time point,
nicotine concentration and experiment are displayed as
mean ± standard deviation (SD). Different symbols are used to dis-
tinguish fold change values determined in different experiments
with 3D aggregating brain cultures.
The responsiveness of the 3D cells to drug treatment was evalu-
ated by calculating – separately for each CYP, cell batch and mea-
surement time point – the Lowest Observed Effect Concentration
(LOEC), i.e. the lowest concentration for which a ﬁxed, pre-deﬁned
threshold for the fold change was exceeded. To derive this ﬁxed
threshold, all the fold change values that were obtained for CYP
expression in untreated 3D cell cultures were log2-transformed.
Then, arithmetic mean and standard deviation (SD) of all these
log2 fold change values were calculated. Biological relevance limits
for the log2 fold change values were set to mean ± 2 ⁄ SD. The two
computed biological relevance limits were back-transformed to





































Oligonucleotide primers and probes used for quantitative analysis of CYPs mRNA expression.
Target gene Primer/probe Sequences 50 to 30 Ref.
Cyclophilin A Forward CTGATGGCGAGCCCTTG This study
Reverse TCTGCTGTCTTTGGAACTTTGTC
Probe CGCGTCTGCTTCGAGCTGTTTGCA















CYP2D2 Forward TGAGTGGCGAGAGCAGAG Mrozikiewicz et al. (2010)
Reverse CGAGCATAAACAAGGGAGG
CYP2E1 Forward CCTTTCCCTCTTCCCATCC Mrozikiewicz et al. (2010)
Reverse AACCTCCGCACATCCTTCC
CYP2D4/2D6 Forward AGCTTCAACACCGCTATGGT Yoshida et al. (2002)
Reverse CAGCAGTGTCCTCTCCATGA
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statistical evaluation of signiﬁcance of fold changes with respect
to the mean band intensity obtained for liver samples (set as 1)
was performed using nonparametric Mann–Whitney U-test, and
P-values below 0.5 were considered as signiﬁcant.Fig. 1. Relative mRNA content of selected isoforms of CYP in untreated 3D
aggregating brain cell cultures. The pie chart illustrates the relative proportion of
expression (in %) of CYP1A1, 2B1, 3A1, 2D2, 2D4/2D6 and 2E1 in control samples
measured by qRT-PCR. The expression levels of CYP1A2 and CYP3A2 were below the
limits of detection.3. Results
3.1. Preliminary studies
The appropriateness of three housekeeping genes (18S RNA,
Cyclophilin A and Beta-actin) to be used as reference for the quan-
tiﬁcation of CYP levels was evaluated under different experimental
conditions. Cyclophilin A was selected due to its stable expression
characteristics. The concentrations of nicotine (50–200 lM) were
chosen in order to be <LOEC for toxicity determined after 44 h of
















3743.2. CYP expression in 3D cell cultures
CYPs mRNA expression levels were measured in untreated 3D
cell cultures. Each CYP level was calculated as the mean value
among the available different batches, and normalized with
respect to the housekeeping Cyclophilin A content. In these control
samples, CYP2B1, CYP1A1, CYP3A1, CYP2D2, CYP2D4/2D6 and
CYP2E1 expression was clearly detectable, whereas the expression
levels of CYP1A2 and CYP3A2 were below the limits of detection
(data not shown). On average, relative mRNA content (with respect
to the total CYP-mRNA) of CYP2B1, CYP1A1, CYP3A1, CYP2D2,
CYP2D4/2D6 and CYP2E1 in untreated 3D cell cultures was highest
for CYP1A1 (50%) and CYP2B1 forms (27%). Moderate expression
levels were detected for CYP3A1 and CYP2D2 (10% each), while
only a small contribution from CYP2D4/2D6 (2%) and CYP2E1
(1%) was found (Fig. 1). Relative contents of CYP2E1, 2D4 and
2B1 were almost constant over three independent cell culture pre-
parations, for both developmental stages (DIV20 and 33); CYP1A1
was highly variable, with levels between 30% and 54% and CYP2D2
and 3A1 varied from 8% to 15%. Each value was reported as an
average among culture replicates, among which some variabilityPlease cite this article in press as: Vichi, S., et al. Cell type-speciﬁc expression a
rat brain cell cultures. Toxicol. in Vitro (2015), http://dx.doi.org/10.1016/j.tiv.2was shown (i.e. CV% was 3–30% for CYP1A1 and 10–35% for
CYP2B1).3.3. Spatial distribution and cell type-speciﬁc localization of CYPs
Cellular localization of CYP1A1, 2B1/B2, 2D4, 2E1 and 3A was
analyzed by immunohistochemistry using intracellular neuroﬁla-
ments (NF) – phosphorylated and non-phosphorylated – and
microtubule-associated protein-2 (MAP2) as neuronal markers,
glial ﬁbrillary acidic protein (GFAP) as astrocyte marker, and mye-
lin basic protein (MBP) as a marker of oligodendrocytes.
CYP1A1 labeling mainly appeared around the cell nuclei and
yellow co-localization signal was found with both NF and GFAP,
and to some extent also with MBP (Fig. 2A), indicating CYP1A1
expression in neurons and astrocytes and to some extent also in
oligodendrocytes.
CYP2D4 labeling had primarily a cell-body and cellular process
distribution (Fig. 2B). Some perinuclear and somal CYP2D4 labeling
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CYP2D4 is primarily expressed in astrocytes. Only faint CYP2D4
co-localization was seen with MBP (Fig. 2B).
Labeling of CYP2E1 was also located around the nucleus and in
the cell body: co-localization with NF was primarily perinuclear asFig. 2. Immunolabeling of DIV35 aggregates for cell type-speciﬁc- and spatial- distribut
CYP1A1; colocalizing with glial ﬁbrillary acidic protein (GFAP; as marker of astrocytes) in
(NF; as marker of neurons), and somatically to little extent with myelin basic protein (M
processes distribution when colocalized with NFs; somatic colocalization with GFAP. F
CYP2E1 and NF. Somatic distribution of CYP2E1, colocalizing with GFAP, and to little exte
extent with MAP2 and GFAP. (E) Primarily perinuclear localization of CYP3A, showing m
bar indicates 100 lm, and 20 lm in the inset. White lines encircle the nuclear localizati
Please cite this article in press as: Vichi, S., et al. Cell type-speciﬁc expression a
rat brain cell cultures. Toxicol. in Vitro (2015), http://dx.doi.org/10.1016/j.tiv.2shown by overlapping Hoechst labeling and CYP2E1-NF co-local-
ization (Fig. 2C, inset). CYP2E1-GFAP co-localization appeared pri-
marily in the cell body (Fig. 2C, insets). CYP2E1 co-localization
signal with MBP was weak (Fig. 2C), suggesting primarily neuronal
and astroglial localization of CYP2E1.ion of CYP1A1, 2D4, 2E1, 2B1/2B2 and 3A. (A) Somatic- and perinuclear labeling of
both compartments, perinuclear colocalization to some extent with neuroﬁlaments
BP; as marker of oligodendrocytes). (B) CYP2D4 labeling show somatic and neural
aint somatic colocalization of CYP2D4 and MBP. (C) Perinuclear colocalization of
nt with MBP. (D) Primarily perinuclear distribution of CYP2B1, colocalizing to some
oderate co-localization with NF and GFAP, and little co-localization with MBP. Scale
on revealed by Hoechst.
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tributed around the nuclei, as indicated by overlapping with
Hoechst; co-localization could be detected to some extent with
both MAP2 and GFAP (Fig. 2D, insets), indicating CYP2B1/2B2
expression in both neurons and astrocytes (not tested in
oligodendrocytes).
Finally, CYP3A labeling was very weak and primarily distributed
around the nuclei (Fig. 2E and inset). Little CYP3A co-localization
was found with NF and MBP, whereas GFAP co-localized to a
greater extent (Fig. 2E, insets), indicating that CYP3A expression
is mainly astrocytic.
3.4. Relative CYP-protein content in aggregating brain cell cultures as
compared to adult liver and brain
Relative protein levels of CYP1A1, 2D4, 2E1, 2B1/2B2 and 3A1
were analyzed in whole protein lysates of adult rat liver, adult
rat brain and in vitro mature aggregating brain cell cultures. The
quantiﬁcation of band intensity for each CYP-isoform is expressed
relatively to the band intensity found in adult liver homogenates
(Fig. 3).
CYP1A1 antibody revealed a band, corresponding to its pre-
dicted molecular weight of 55 kDa (Fig. 3A, lower panel) and band
intensities in brain and aggregate cultures appeared stronger as
compared to the liver (approximately 5- to 6-fold, Fig. 3B). The
same trend was observed in the case of CYP2D4, where – although
highly variable – the corresponding 56 kDa-band was more
intense in brain and aggregate culture lysates as compared to liver
(Fig. 3A lower panel, and B). However, despite this variability,
CYP1A1 and 2D4 detection in aggregates seem to follow the same
tendency as the in vivo brain, with higher quantities as compared
to liver.
CYP2E1, 2B1/2B2 and 3A1 bands were detected at their respec-
tive molecular sizes of 60-, 50- and 50 kDa in liver-, brain- and
aggregate culture lysates (Fig. 3A, lower panel). However, when
quantiﬁed, band intensities for all three proteins were weaker in
brain and aggregate culture lysates as compared to liver (Fig. 3B).
Overall, this indicates that the three CYP-isoforms are weaklyFig. 3. Immunoblotting of CYP1A1, 2D4, 2E1, 2B1/2B2 and 3A, and relative quantiﬁcatio
ponceau staining of equal protein load of liver (2nd lane), brain (3rd lane) and aggregates
in kilo Dalton (kDa). (A) Bottom panel: representative blots of CYP-isoforms detected
Relative quantiﬁcation of different CYPs. Each point represents the relative band intens
tissues. The statistical signiﬁcance of fold changes was performed using nonparametric
Please cite this article in press as: Vichi, S., et al. Cell type-speciﬁc expression a
rat brain cell cultures. Toxicol. in Vitro (2015), http://dx.doi.org/10.1016/j.tiv.2expressed in the brain cells as compared to liver. Again, CYP2E1,
2B1/B2 and 3A1 expression in aggregates appears comparable to
that of in vivo brain.3.5. Inducibility of CYPs by nicotine treatment
The responsiveness of the 3D cell cultures to nicotine treatment
was evaluated as outlined in the statistical analysis section.
As outcome of these computations, the following biological rele-
vance limits were obtained: lower limit = 0.677-fold, upper
limit = 1.429-fold. These two limits are indicated by the horizontal
lines that are displayed in each of the six panels of Fig. 4.
For CYP2B1, in ﬁve experiments (II–VI) with 3D cell cultures
prepared from three independent pools of embryonic rat brains,
no up-regulation of CYP2B1 expression was observed after nicotine
treatment (Fig. 4, upper panel). Only in experiment I, performed on
aggregates coming from a fourth pool of embryonic brains, a con-
sistent induction of CYP2B1 was observed upon 24 and 48 h nico-
tine treatment (Fig. 4). Here, 48 h-treatment increased CYP2B1
expression up to 13.5-fold, as compared to the constitutive
CYP2B1. In summary, excluding results from experiment I, sta-
tistical evaluation of CYP2B1 expression data failed to show a con-
sistent and biologically relevant induction effect after nicotine
treatment.
Statistical evaluation of CYP1A1 expression indicate minute
induction capability of nicotine, with fold change values above
the upper threshold for at least one nicotine concentration and
time point in three out of six experiments (Fig. 4, lower panel).
Again, limited to batch I, a biologically relevant induction after
24- and 48 h nicotine treatment was also observed (Fig. 4), with
up to 2.5-fold increased mRNA expression as compared to controls.
However, this increase was not concentration dependent and
showed only a modest trend toward higher levels with increasing
time.
CYP1A1 and 2B1 expression levels observed in control samples
and after nicotine treatment were comparable between the tested
developmental stages (DIV 20 and DIV 33) (Fig. 4).ns thereof, in liver, brain and DIV35 aggregates. (A) Top panel shows representative
(4th lane) lysates on blotted membrane. First lane shows molecular weight marker
with antibodies speciﬁc for each isoform in liver, brain and aggregate lysates. (B)
ity as compared to the mean band intensity of liver samples (set as 1). N = 3 for all
Mann–Whitney U-test; P-values below 0.5 were considered as signiﬁcant.































































Fig. 4. CYP2B1 and CYP1A1 mRNA expression levels after nicotine treatment. Graphical representation of fold change values to control obtained for CYP2B1 and CYP1A1 from
six different experiments of 4, 24 and 48 h exposure to 50, 100 or 200 lM nicotine. Plotted values are replicate culture-means ± standard deviation (SD). Filled symbols
connected with dotted lines indicate DIV20, and open symbols connected with full lines DIV33.
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To our knowledge, this is the ﬁrst study aimed to characterize
CYP-content of 3D brain cell cultures. The constitutive metabolic
competence is a particularly important feature, knowing that the
drug metabolizing CYP-dependent system in the brain can play a
crucial role in the local biotransformation of endogenous and
exogenous compounds, such as centrally acting drugs, neurotoxins,
and neurochemicals.
The two major limitations in using results from in vitro models
to evaluate the risk related to neurotoxic effects of chemicals, or
safety during drug development, is the complexity of the cell types
characterizing the brain, in addition to scant knowledge of the
biokinetic parameters. Neurotoxicity has been identiﬁed as a fre-
quent adverse drug effect, contributing to the termination of up
22% of drug candidates (Watkins, 2011). It is known that
bioavailability/biokinetics of a chemical is a key element in elicit-
ing toxic effects for a drug candidate. Indeed, most CNS-targeting
drugs have been withdrawn because of poor blood brain barrier
permeability; once demonstrated they reach the target, the
insufﬁcient characterization of metabolic competence of the avail-
able model does not allow an estimation of the possible in situ
biotransformation.
Aggregating brain cell cultures prepared from embryonic rat
brains address the ﬁrst issue, containing different types of brain
cells (i.e., neurons, astrocytes, oligodendrocytes, and microglia),
able to grow and mature in serum-free, chemically deﬁned med-
ium, and form highly differentiated structures and functional neu-
ronal networks (Honegger et al., 1979). The histotypic organization
of the cells within the 3D structure is close to the situation in vivo;
thus, 3D aggregating brain cell cultures constitute a useful systemPlease cite this article in press as: Vichi, S., et al. Cell type-speciﬁc expression a
rat brain cell cultures. Toxicol. in Vitro (2015), http://dx.doi.org/10.1016/j.tiv.2for neurotoxicological studies. The model allows detection of toxi-
city of chemicals affecting selectively either the neurons or the
glial cells after acute and repeated exposure (Zurich et al., 2013;
Bellwon et al., in press; Pomponio et al., in press). Furthermore,
organophosphorous pesticides such as parathion and chlorpyrifos,
requiring metabolic activation via cytochrome P450, exhibited
organ-speciﬁc toxicity (Monnet-Tschudi et al., 2000), indirectly
suggesting that cells in the model possess some metabolic activity.
The present results clearly indicate that several CYPs, namely
1A1, 2B1, 3A, 2D2, 2D4 and 2E1, are constitutively expressed in
3D aggregating brain cell cultures, with the ﬁrst two in the list
accounting for 2/3 of the total CYP-mRNA detected. The establish-
ment of relative proportions of the different isoforms cannot be
made at the protein levels in this study, since they were not
detected as absolute content, but only quantiﬁed relatively to liver
homogenates. Moreover, in analogy to the in vivo situation (Miksys
et al., 2000; Miksys and Tyndale, 2002; Ravindranath et al., 1995),
CYP proteins are differently localized in the various cell types.
Regarding CYP1A1, our data, showing localization in both neu-
rons and astrocytes and scarcely in oligodendrocytes, are in agree-
ment with published data indicating a signiﬁcant mRNA and
protein expression of CYP1A1 in cultured rat brain neurons and
glial cells (Kapoor et al., 2006). As shown by western blot,
CYP1A1 content in brain as well as in 3D aggregates is higher than
in liver, where constitutive expression is described to be low
(Drahushuk et al., 1998; Chinta et al., 2005), this isoform being
mainly an extra-hepatic isoform. The presence of CYP2B1 has been
shown in different regions of rat brain, in neurons and glial cells
(Miksys et al., 2000; Rosenbrock et al., 2001; Volk et al., 1991).
Also in this case our results show that the in vitromodel maintains
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18 March 2015glial and neuronal cell populations, likely distributed in the perinu-
clear area. CYP2B protein detection was highly variable in liver-,
brain- and aggregate samples, not allowing to draw deﬁnite con-
clusions on the relative content. For CYP2E1 and CYP3A, moderate
to low levels of mRNA were measured in 3D cultures, with barely
detectable protein amounts of respective CYPs compared to liver
and a marked difference in cellular distribution. In vivo, CYP2E1
was found in the midbrain in cells with the morphological charac-
teristics of dopaminergic neurons (Riedl et al., 1996), while various
results were reported regarding its presence in astrocytes
(Hansson et al., 1990; Watts et al., 1998). In aggregating rat brain
cell cultures, CYP2E1 was localized in both neurons and astrocytes.
For CYP3A, results are in line with in vivo data showing a lower
expression of CYP3A in brain than in liver (Woodland et al.,
2008), although inter-individual variability of CYP3A expression
in liver appears to be high. In the brain aggregates, CYP3A was
found mainly in astrocytes whereas limited information is avail-
able on its in vivo cellular localization. For CYP2D4, protein expres-
sion appeared concentrated mainly in astrocytes, while less was
found in neurons and oligodendrocytes. In this study – as pre-
viously reported in vivo (Hiroi et al., 1998; Chinta et al., 2002) –
CYP2D4 levels were higher in brain tissue as compared to liver,
again CYP2D4 levels in 3D brain cell cultures were similar to brain.
In vivo, chronic exposure to nicotine speciﬁcally induces brain
CYPs, mainly in neurons (Jacob et al., 1997; Miksys et al., 2000;
Zevin and Benowitz, 1999), whereas the total CYP content in the
liver remains unaffected (Anandatheerthavarada et al., 1993;
Miksys et al., 2000; Yue et al., 2008). Neurons and glial cells
in vitro have also been shown to respond to CYP1A1/1B1 inducers
(Jacob et al., 1997; Kapoor et al., 2006; Miksys et al., 2000).
In the present study, the quantiﬁcation of CYP1A1 and CYP2B1
mRNA levels was used as a marker of induction, as previously
reported (Meredith et al., 2003; Pavek and Dvorak, 2008).
However, after short-term exposure to nicotine mRNA content
showed highly variable results. A plausible explanation arises from
the observed variations in the relative proportions of the con-
stitutive CYPs among culture preparations, possibly due to varia-
tions in the proportions of the different type of cells, or to
individual variations in the rat embryos used to prepare the cul-
tures, as well as to the short duration of exposure to nicotine.
Indeed, strong induction of CYP2B1 has been reported after long-
term treatment with nicotine (Khokhar et al., 2010). Our data
shows the potentiality of 3D aggregating brain cells to be respon-
sive to inducers, although before concluding on this issue, longer
exposure time and other prototype inducers should be used.
Furthermore, protein levels after exposure to inducers should be
monitored. In this respect, preliminary results showed increased
immunolabeling of CYP1A1 after 48 h exposure to nicotine (not
shown).
In the present work, no evidence of mRNA induction after nico-
tine treatment was found for CYP2E1, CYP3A AND CYP2D families.
Consistently, after nicotine exposure the induction of brain CYP2E1
and 2D has been reported in absence of mRNA increase, suggesting
nontranscriptional regulation (Joshi and Tyndale, 2006; Yue et al.,
2008).
The present ﬁndings, showing the expression of CYP1A1,
CYP2B1/B2, CYP2D4, CYP2E1 and CYP3A isoforms in 3D aggregat-
ing rat brain cell cultures, together with previously reported obser-
vations on the deleterious effects of organophosphorous pesticides
(Monnet-Tschudi et al., 2000; Zurich et al., 2000) not simply attri-
butable to the parent compounds, suggest that this model pos-
sesses metabolic capacity. In addition, the recently reported
formation of the major oxidative metabolite of amiodarone in 3D
aggregating rat brain cell cultures after 14-day repeated exposure
(Pomponio et al., in press) constitutes a direct demonstration of
the functionality of the detected CYPs. Indeed, the isoforms knownPlease cite this article in press as: Vichi, S., et al. Cell type-speciﬁc expression a
rat brain cell cultures. Toxicol. in Vitro (2015), http://dx.doi.org/10.1016/j.tiv.2to metabolise amiodarone, an antiarrhythmic drug causing neuro-
toxic side-effects in some patients following long-term treatment,
belong to the CYP3A, 2C, 1A and 2D family in rodents and in
humans (Zahno et al., 2011), and most of them have been demon-
strated here to be constitutively expressed in this 3D cell culture
model.
Although requiring further conﬁrmation by measuring
CYP-activity, these results suggest an intrinsic metabolic capacity,
most likely contributing to the high performance of this culture
model in neurotoxicological studies, and support its use in
studying brain toxication/detoxication mechanisms.Conﬂict of Interest
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